VERAXA Biotech Leverages AI in Collaboration with Ardigen to Advance BiTAC(R) Cancer Therapy Platform

Artificial intelligence is becoming an increasingly important tool for drug discovery, with major pharmaceutical companies expanding AI collaborations across oncology and immunology. Against that backdrop, VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-focused research partner Ardigen to strengthen development of its BiTAC(R) cancer therapy platform through AI-enabled target discovery and validation. The partnership reflects a broader trend toward combining computational biology with next-generation antibody therapeutics to improve research productivity.

The agreement brings together VERAXA's antibody engineering capabilities with Ardigen's expertise in artificial intelligence, computational biology and bioinformatics. Ardigen, headquartered in Kraków, Poland, with U.S. operations in San Francisco, has supported more than 700 discovery projects. The collaboration aims to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks. VERAXA's Boolean "AND-gated" BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design.

AI analysis of historical clinical and preclinical datasets could help identify promising targets that were previously abandoned because of safety concerns. This approach could accelerate the development of safer, more effective cancer therapies. For more details on the collaboration, visit https://ibn.fm/yoDH5.

The partnership underscores the growing impact of AI on drug R&D, especially in oncology where complex biological data require advanced analytical tools. VERAXA's focus on novel T-cell engagers and antibody-drug conjugates positions it to benefit from AI-driven insights that can optimize target selection and therapeutic design. As AI continues to reshape pharmaceutical research, companies like VERAXA that integrate these technologies early may gain a competitive advantage.

For investors, the collaboration signals VERAXA's commitment to leveraging cutting-edge tools to advance its pipeline. The company's BiTAC(R) platform, designed to selectively activate T-cells only in the presence of two tumor-associated antigens, aims to reduce off-target toxicity—a common challenge in cancer immunotherapy. By incorporating AI, VERAXA hopes to expand the range of targetable cancers and improve clinical outcomes.

Latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.